
1. Participant Flow: A flow diagram showing participants involved at each stage. Patient Screening Flow-Chart



Note. 1. Consecutive randomization **2.** Test products allocation were blinding b/w physician-nurse-patients **3.** Each of any one of two set of test products contained matching computerized allocated randomization numbers as series on products.

2. Baseline Characteristics: A summary showing baseline demographic (age and gender) and clinical characteristics of the participants.

Control (N=21)	Active(N=21)	
Mean (SD), Min-Max,	Mean (SD) ,	P-Value
Range	Min-Max, Range	
21	21	
48.90 (6.09) 39-62, 23	47.00 (5.42) 39-58, 19	0.291
59.00 (6. 05) 48-68, 20	60.81 (5.97) 49-74, 2	0.336
159 . 28 (6.93) 150 - 150, 2	160 . 23 (5.94) 149-170, 21	0.636
4 (19.0 %)	7 (33 .3%) ,	
5 (23 .8%) ,	11 (52 .4%) ,	*0.157
12 (57 .1%) ,	3 (14 . 3 %)	
3 (14 . 3 %) ,	11 (50.0 %) ,	
17 (80.9 %) 1 (4.8 %)	10 (45 .2%) 1 (4.8%)	*0.025
	Mean (SD), Min-Max, Range 21 48.90 (6.09) 39-62, 23 59.00 (6.05) 48-68, 20 159.28 (6.93) 150-150, 2 4 (19.0%) 5 (23.8%), 12 (57.1%), 3 (14.3 %), 17 (80.9%)	Mean (SD), Min-Max, RangeMean(SD), Min-Max, Range212148.90 (6.09) 39-62, 2347.00 (5.42) 39-58, 1959.00 (6.05) 48-68, 2060.81 (5.97) 49-74, 2159.28 (6.93) 150-150, 2160.23 (5.94) 149-170, 214 (19.0%)7 (33.3%), 149-170, 215 (23.8%), 12 (57.1%), 3 (14.3%)11 (50.0 %), 10 (45.2%)

 Table. 1 Demographic Characteristics

P-value by T-test, * P-value by Chi-Square Test

Clinical Characteristics	Control (N=21)	Active (N=21)	
	Mean (SD) ,	Mean (SD),	P - Value
	Min-Max, Range	Min-Max, Range	
Gender Female	21	21	
Family History of CVI	Yes (0) , No (21)	Yes (0) , No (21)	-
Medical His-Comorbid		.,,	
None	16 (76 . 2 %) ,	17 (80 .1%) ,	
Hypertension	5 (24 .2%) ,	2 (9.7 %) ,	*0.191
Musculoskeletal	0 (0%)	2 (9.7 %)	
Co-Medic (Self-Care)			
Sometime	17 (99 E 0 4)	16 (77 9 0 6)	*0 707
Degular	17 (82.5 %) ,	16 (77 .8%) ,	*0.707
Regular	4 (17 . 5 %)	5 (22 .3%)	
CEAP Classification			
CEAP C1	8 (38.0 %) ,	10 (47.6 %)	*0.533
CEAP C2	13 (62.0 %)	11 (52 .4%)	
SBP (mmHg)	138.95 (4.44)	137.86 (4.06)	0.410
	129.0-146.0, 17.0	130.0-145.0,15.0	
DBP (mmHg)	88.04 (3.90)	88.57 (2.54)	0.609
· · · · · · · · · · · · · · · · · · ·	78.0-97.0, 19.0	83.0-92.0, 9.0	
Heart Rate (time per	70.81 (4.08)	70 . 33 (4.68)	
minute)	64.0-78.0, 14.0	60.0-78.0, 18.0	0.727
Numbers of Leg	3.71 (0.902)	3.05 (0.669)	*0.087
5			0.007
Symptoms (symptom-	3 - 6, 3	2 - 4, 2	
Table 3)			

Table. 2 Clinical Characteristics (A)

P-value by T-test, * P-value by Chi-Square Test

	Control (N=21)	Active (N=21)	
Leg Symptoms	Number (%) ,	Number (%) ,	P-Value
Heavy Leg			
Yes	7 (43.7 %)	9 (56 .3%)	*0.525
No	14 (53.8 %)	12(46.2%)	
Leg Swelling			
Yes	6 (56.7 %)	9 (43.3 %)	*0.334
No	15 (40.0 %)	12 (60.0 %)	
Leg Paiin			
Yes	21 (50.0 %)	21 (50.0 %)	-
No	0 (0%)	0 (0%)	
Night Cramp			
Yes	12 (57 .1%)	7 (33.3 %)	*0.121
No	9 (42.9 %)	14 (66.7 %)	
Burning Sensation			
Yes	0 (0%)	0 (0%)	-
No	21 (100 %)	21 (100 %)	
Pin / Itching in Leg			
Yes	1 (4.8 %)	0(0%)	*0.050
No	20 (95.2 %)	21 (100.0 %)	
Leg Itching			
Yes	10 (47 .6%)	4 (19.1 %)	*0.311
No	11 (52.4 %)	17 (80 .9%)	
Varicose Vein			
Yes	18 (85.7 %)	11 (52 .4%)	*0.019
No	3 (14 . 3%)	10 (47 .6%)	
Spider Veins			
Yes	3 (50.0 %)	3 (50.0 %)	-
No	18 (50.0 %)	18 (50.0 %)	

Table. 3 Clinical Characteristics (B)

* P-value by Chi-Square Test

3. The Outcome Measures: Primary Outcomes-Responder Rate

Table. 4 Venous Clinical Severity Score (VCSS). Responder -50 % Score Reduction(all patients)

I			
VCSS	Control (N=21)	Active (N=21)	
Total Score	Numbers with 50%	Numbers with 50%	P-Value
50%	Score reduction	Score reduction	
Reduction	N/Total (%)	N/Total (%)	
After 4 weeks	2/21 (9.52%)	12/21 (57.14 %)	*P=0.003
After 8 weeks	3/21 (14.28%)	12/21 (57.14 %)	*P=0.009
After 12 weeks	4/21 (19.04%)	12/21 (57.14 %)	*P=0.025
*Develue Fisher's Event			

*P-value – Fisher's Exact

Outcome Measures: Secondary Outcomes-Responder Rate Analysis by Attributes

 Table. 5
 Venous Clinical Severity Score (VCSS).
 Responder -50 %
 Score Reduction

(Based on Severity CEAP Classification)

VCSS	Control (N=21)	Active (N=21)	
Total Score 50%	Numbers with 50%	Numbers with 50%	P-Value
Reduction	Score reduction	Score reduction	
	N/Total (%)	N/Total (%)	
After 4 weeks			
CEAP Class 1	0/8 (0%)	6/10 (60.0 %)	*P=0.013
CEAP Class 2	2/13 (15.38 %)	6/11 (54.54 %)	*P=0.082
All CEAP Class 1+2	2/21 (9.52%)	12/21 (57.14 %)	*P=0.003
After 8 weeks			
CEAP Class 1	0/8 (9.52 %)	6/10 (60.0 %)	*P=013
CEAP Class 2	3/13 (23.07 %)	6/11 (54.54%)	*P=0.206
All CEAP Class 1+2	3/21 (14.28 %)	12/21 (57.14 %)	*P=0.009
After 12 weeks			
CEAP Class 1	0/8 (9.52 %)	6/10 (60.0 %)	*P=0.013
CEAP Class 2	4/13 (30.76 %)	6/11 (54.54%)	*P=0.408
All CEAP Class 1+2	4/21 (19.04 %)	12/21 (57.14 %)	*P=0.025
All responder	4/21 (19.04%)	12/21 (57.14%)	*P=0.025

*P-value – Fisher's Exact

Table. 6 Venous Clinical Severity Score (VCSS). Responder -50 % Score Reduction(Based on Presence of Co-morbidity)

VCSS	Control (N=21)	Active (N=21)	
Total Score 50%	Numbers with 50%	Numbers with 50%	P-Value
Reduction	Score reduction	Score reduction	
	N/Total (%)	N/Total (%)	
After 4 weeks			
No Comorbidity	1/16 (6.25%)	9/17 (52.94 %)	*P=0.007
With Comorbidity	1/5 (20.0 %)	1/4 (25.0 %)	*P=0.206
All Patients	2/21 (9.52%)	12/21 (57.14 %)	*P=0.003
After 8 weeks			
No Comorbidity	2/16 (12.50%)	9/17 (52 . 94 %)	*P=026
With Comorbidity	1 / 5 (20.0 %)	3/4 (75.0 %)	*P=0.206
All Patients	3/21 (14 . 28 %)	12/21 (57.14 %)	*P=0.009
After 12 weeks			
No Comorbidity	3/16 (18.75 %)	9/17 (52 .9%)	*P=0.071
With Comorbidity	1/5 (20.0 %)	3/4 (75.0 %)	*P=0.206
All Patients	4/21 (19.04 %)	12/21 (57 . 14 %)	*P=0.025
All responder	4/21 (19.04 %)	12/21 (57.14 %)	*P=0.025

*P-value-Fisher's Exact(Hyprtension7/42, Musculoskeletal Disorder2/42, No-comorbidity 33/42)

Disability assessed as Venous Clinical Severity Score (VCSS)-Total

VCSS	Control (N=21)	Active (N=21)	
Total Sore	Mean(SD),	Mean (SD),	*P-value
	95% CI, Min-Max	95%CI Min-Max	
Day 0	27.2321 (6.4908),	25.0000 (6.0917),	
	24.2775 - 30.1850,	22.2271 - 27.7729,	*0.257
	12.50-37.50	15.63-34.38	
Week 4	22.4702 (7.9438),	11.9048 (6.4908),	
	18.8542 - 26.0862,	7.9673 - 15.8422,	*<0.001
	9.38-37.50	0.00-31.25	
Week 8	22.0238 (7.6849),	17.1131 (8.3791),	
	18.5257 - 25.5220,	8.3880 - 16.0168,	*<0.001
	9.38-37.50	0.0-31.25	
Week 12	21.7262 (7.4647),	12.2024 (8.1432),	
	18.3457 - 25.5220,	8.4956 - 15.9092,	*<0.001
	9.38-37.50	0.0-31.25	

 Table. 7 Venous Clinical Severity Score (VCSS). * Total Score

* P-value T-test (Active vs Controlled)

PRSPS-	Control (N=21)	Active (N=21)	*P-
Total Score	Mean(SD), 95% CI, Min-Max	Mean (SD),95%CI, Min-Max	value
Day 0	42 . 9630 (7 . 0038) ,	37 . 1429 (6 . 8545) ,	
	39.7749 - 46.1511, 33.33-57.78	34.0027 - 40.2630, 24. 44-51.11	0.010
Week 1	42.4339 (10.2222) ,	30 . 8995 (9 . 4256) ,	
	37.7555 - 47.1122, 26.67-60.00	26.6090 - 35.1900, 20.00-60.00	<0.001
Week 2	39.7884 (9.8106) ,	29 . 5238 (8 . 1994) ,	
	35.3226 - 44.2541, 24.44-55.56	25 . 7915 - 33 . 2562, 20 . 00-53 . 33	0.001
Week 3	38 . 5185 (9 . 9711) ,	27 . 3016 (8 . 4952) ,	
	33.9797 - 43.0573, 22.22-53.33	23.4346 - 31.1686, 20.00-51.11	<0.001
Week 4	38 . 4021 (9 . 9001) ,	26.7725 (8.0294) ,	
	31.8958 - 40.9086, 22.22-53.33	23.0356 - 30.5094, 20.00-46.67	0.001
Week 8	35 . 7672 (9 . 4256) ,	26.1376 (8.4006) ,	
	31.4767 - 40.0577, 22.22-51.11	22.3137 - 29.9615, 20.00-40.89	0.001
Week 12	35.8730 (10.7562) ,	25 . 9259 (8 . 0226) ,	
	30.9768 - 40.7692, 22.22-53.33	22.2741 - 29.5778, 20.00-48.89	0.002

 Table. 8 Physician Rated Symptom Perception Score (PRSPS) Total Score

*P-Value T-test (Active VS Controlled)

PSSS Total	Control (N=21)	Active (N=21)	*P-value
Score	Mean (SD) , 95% Cl, Min-Max	Mean (SD) , 95% Cl, Min-Max	
Day 0	35 . 2585 (8.0086) ,	31.7211 (6.2347) ,	
	27.2499 - 43.2671, 30.86-50.57	25.4864 - 37.9558, 26.71-38.57	P=0.118
Week 1	24 . 8980 (7.4151) ,	19 . 2449 (5.0210) ,	
	17.4831 - 32.4041, 26.71-38.57	14.2239 - 24.2659, 12.14-31.14	P=0.006
Week 2	23 . 0680 (7 . 7269) ,	17 . 1020 (4 . 8117) ,	
	15.3411 - 30.7949, 26.86-37.29	12.2903 - 21.9137, 17.57-28.29	P=0.005
Week 3	23 . 0816 (7 . 7273) ,	16 . 9864 (5.0209) ,	
	15.3543 - 30.8089, 26.86-37.14	23.4346 - 31.1686, 19.57-29.43	P=0.004
Week 4	22.9524 (7.7321),	16 . 8639 (4.9864) ,	
	15.2203 - 30.6845, 26.86-36.86	11.9655 - 21.8503, 19.57-29.43	P=0.004
Week 8	22 . 9592 (7.6331) ,	16.7347 (4.7568) ,	
	15.3261 - 30.5923, 27.57-36.86	11.9779 – 21.4915, 18.57-28.14	P=0.003
Week 12	22 . 8571 (7 . 5951) ,	16 . 6803 (4.6080) ,	
	15.2620 - 30.4522, 25.86-35.86	12.0723 - 21.2883, 19.00-29.00	P=0.003

 Table. 9
 Patient Self-Rated Symptom Score (PSSS).
 Total Score

*P-Value T-test (Active Vs Controlled)

Table. 10 Medical Outcomes Study 12-Items Short-Form General Health Survey (MOS SF 12) –Physical Component Summary Score (PCS), Mental Component Summary Score (MCS) andGlobal Score (Control Treatment– Baseline – the end of trial -Week 12)

MOS –Item	Control (N=21)-Day 0	Control (N=21)- Week 12	P-value
SF 12	Mean (SD) , 95 % CI, Min-Max	Mean (SD) , 95 % CI, Min-Max	
PCS	84 . 6032 (3.06887) ,	92 . 3810 (2 . 3904) ,	<.0.001
	76.67 – 90.00,13.33	86.67 - 93.33,6.67	
MCS	86 . 1905 (2.4234),	86 . 3492 (2 . 5614) ,	0.496
	76.67 -90.00,13.33	80 - 93.33,13.33	
Global	85 . 3965 (1.8184),	89 . 3651 (2 . 0052) ,	<0.001
Score	81.67 - 88.33,6.67	83.33 -93.33, 10.00	

Table. **11** Medical Outcomes Study 12-Items Short-Form General Health Survey (MOS SF 12) – Physical Component Summary Score (PCS), Mental Component Summary Score (MCS) and Global Score

(Active Treatment – Baseline - the end of trial- Week 12)

Active (N=21)-Day 0	Active (N=21)-Week 12	P-value
Mean (SD) , 95% CI, Min-Max	Mean (SD) , 95% Cl, Min-Max	
84.7619 (2.7021) ,	92.5397 (1.7965) ,	<0.001
80.00 -90.00,10.00	86.67 - 93.33,6.67	
86 . 8254 (0 . 7273) ,	86 . 3492 (1 . 4547) ,	0.245
86.67 - 90.00,3.33	80 - 86.67,6.67	
85.7937 (1.3559) ,	89 . 4444 (1 . 0971) ,	<0.001
83.33 - 85.33, 5.00	86.67 -90.00, 3.33	
	Mean (SD), 95% Cl, Min-Max 84.7619 (2.7021), 80.00 -90.00,10.00 86.8254 (0.7273), 86.67 - 90.00,3.33 85.7937 (1.3559),	Mean (SD), 95% CI, Min-Max Mean (SD), 95% CI, Min-Max 84.7619 (2.7021), 92.5397 (1.7965), 80.00 -90.00,10.00 86.67 - 93.33,6.67 86.8254 (0.7273), 86.3492 (1.4547), 86.67 - 90.00,3.33 80 - 86.67,6.67 85.7937 (1.3559), 89.4444 (1.0971),

*P-value Paired T-Test

Table. 12 Medical Outcomes Study 14-Items Short-Form Chronic Venous Disease Survey (MOSCIVIQ 14) –Pain, Physical Function, Psychological-Social Function and Global Score(Control Treatment- the end of trial Week 12 - Baseline –Day 0)

MOS	Control (N=21)-Day 0	Control (N=21) Week 12	P-value
CIVIQ 14	Mean (SD),Min-Max, Range	Mean (SD) ,Min - Max, Range	
Pain	61 . 4286 (8.0843) ,	67 . 8571 (7.6764) ,	<0.001
	45.00 -75.00,30.00	60.00 - 75.00,15.00	
Physical	58 . 7755 (4. 9597) ,	67 . 3469 (3 . 8075) ,	<0.001
Function	49.29 - 66.43,17.14	60.00 - 75.00,15.00	
Psycholo-	60 . 3571 (5 . 2013) ,	68.6905 (4.3025) ,	<0.001
& Social	47 . 50 - 70 . 0022 . 50	60.00 - 75.00,15.00	
Function			
Global	68.6905 (4.3025) ,	79 . 52 (5 . 5700) ,	<0.001
Score	60.00 - 75.00,15.00	68.57 - 91.43,	

*P-value Paired T-Test

Table. 13 Medical Outcomes Study 14-Items Short-Form Chronic Venous Disease Survey (MOSCIVIQ 14) –Pain, Physical Function, Psychological-Social Function and Global Score(Active Treatment the end of trial -Week 12– Baseline – Day 0)

MOS	Active (N=21)-Day 0	Active (N = 21)- Week 12	P-value
CIVIQ 14	Mean (SD) , Min - Max,	Mean (SD)I, Min-Max,	
	Range	Range	
Pain	63 . 5714 (9 . 3732) ,	70.7143 (6.9436) ,	<0.001
	45.00 - 75.00,30.00	60.00 -75.00,15.00	
Physical	56 . 4286 (5 . 4772) ,	66 . 9388 (3 . 0232) ,	<0.001
Function	49.29 -66.43, 17.14	64.29 -75.00, 10.71	
Psycholo-	61 . 3095 (5.7347) ,	70 . 4762 (2 . 6947) ,	<0.001
& Social	52.50 - 75 . 22, 5.00	65.00 -75.00, 10.00	
Function			
Global	70 . 4762 (2 . 6947) ,	78.70 (5.8000) ,	<0.001
Score	65.00- 75.00,10.00	76.06- 81.34	

*P-value Paired T-Test

3. Adverse Events: A preliminary study on the Adverse Events report for both the Active and Controlled had been published in a separated publication and as such we presented only found as frequency tolerated by patients for the ends of trials.

https://www.tci-thaijo.org/index.php/EAUHJSci/article/view/101887

Table. 14 Report of Adverse Event over 12-weeks period of follow-up.

Summary	Control (N=21)	Active (N=21)	P-Value
Period	Number, (%)	Number, (%)	
	No 7/21 (33.3 %),	No 7/21 (33.3 %),	0.628
Week 4	Some-Tolerate 14/21 (66.7%)	Some-Tolerate 14/21 (66.7%)	
	No 12/21 (57.4 %),	No 14/21 (66.7 %),	0.376
Week 8	Some-Tolerate 9/21 (42.6 %)	Some-Tolerate 7/21 (33.3%)	
	No 20/21 (95.1 %),	No 18/21 (85.7 %),	0.756
Week 12	Some-Tolerate 1/21 (4.9%)	Some-Tolerate 4/21 (14.3%)	

P-value Fisher's Exact Test